Prevagen Class Action Lawsuit Claims Supplement Does Not Actually Support Brain Health

A class action lawsuit has been filed against Quincy Bioscience, the manufacturer of Prevagen, alleging the supplement does not deliver on its promises to protect against Alzheimer’s, dementia, or memory loss. The lawsuit claims the company knowingly misled consumers with deceptive marketing, charging up to $60 per month for a product containing apoaequorin, a jellyfish-derived protein that the manufacturer itself admits is broken down in the stomach and cannot cross the blood-brain barrier to affect brain function.

The complaint further alleges that the company’s primary memory study, the Madison Memory Study, was flawed, unregistered, and manipulated to show benefits that did not exist. The FDA previously warned Quincy Bioscience in 2012 for marketing Prevagen as an unapproved drug, and a 2024 court injunction prohibited deceptive “brain health” advertising.

The lawsuit seeks class action status and requests restitution, damages, and an end to false advertising, alongside a corrective advertising campaign. Previous attempts to consolidate similar lawsuits into multidistrict litigation were denied, but individual cases and regulatory actions, including a recent FTC and New York Attorney General case, continue to challenge the company’s claims.

(Source：AboutLawsuits.com)